Recent 8-K filings for RGBP
Highest-materiality recent filing
Regen Biopharma issues 21.4M shares in Jan 2026 for $69,550, massive dilution
- On Jan 15, 2026, issued 5,000,000 shares to satisfy $11,449 principal + $8,101 interest on convertible debt.
- On Jan 29, 2026, issued 5,302,732 shares to satisfy $12,000 principal + $1,000 interest.
-
Regen Biopharma issues 77.85M shares to settle $68,723 in debt and fees
Issued 77,849,847 common shares between Feb 4-27, 2026 for $53,474 principal, $4,249 interest, $11,000 fees.
-
Regen Biopharma issues 21.4M shares in Jan 2026 for $69,550, massive dilution
On Jan 15, 2026, issued 5,000,000 shares to satisfy $11,449 principal + $8,101 interest on convertible debt.
-
Regen Biopharma declares 1:1 dividend of Series A Preferred stock for all share classes
Board declared dividend of one share of Series A Preferred for each share of Common, Series A, AA, M, and NC Preferred owned.
-
Regen BioPharma issues 23.68M common shares for cash and debt conversion in Oct-Nov 2025
Oct 8, 2025: issued 6.8M shares for $68,000 cash.
-
Issued 20M shares to CEO David Koos for services in planned Phase I trial of HemaXellerate; shares vest upon trial completion.
-
Regen Biopharma raises $58.2K via unregistered sales of 5.82M shares
On Sep 15, 2025, issued 3,320,000 shares for $33,200 to an unaffiliated investor.
-
Regen Biopharma issues $100K convertible note to Labrys Fund at 60% discount conversion
Principal $100,000; net proceeds $85,000 after $15,000 original issue discount.
-
Regen Biopharma enters $130K convertible note financing with CFI Capital
Issued a 6% convertible promissory note for $130,000 principal; $13,000 original issue discount, net proceeds $117,000.
-
Regen Biopharma issues 10M shares to CEO in settlement of $50K accrued salary
Issued 10,000,000 common shares to CEO David R. Koos as settlement for $50,000 of accrued unpaid salary.
-
Regen Biopharma restates FY2024 financials; prior statements not reliable
Non-reliance on unaudited FY2024 financials filed Nov 20, 2024; share compensation and derivative liability corrected.
-
Regen Biopharma dismisses Bush & Associates, engages BCRG Group as new auditor
Dismissed Bush and Associates CPA LLC as independent auditor effective March 31, 2025.
-
Regen Biopharma FY2024 net loss $867k, revenue $237k; cash only $716
Total revenues of $236,560 (incl. $110k related party); operating loss of $418,189.
-
Regen Biopharma declares 1-for-1 stock dividend payable Nov 1
Dividend of one common share for each share of common and Series A, AA, M, NC preferred stock held.
-
Regen Biopharma issues $250K promissory note to Coventry; $25K OID, convertible on default
Principal amount $250K; original issue discount $25K, net proceeds $200K.
-
Regen Biopharma appoints Bush and Associates CPA as new independent auditor effective May 28, 2024
Audit committee approved engagement of Bush and Associates CPA LLC as independent auditor on May 28, 2024.
-
Regen Biopharma declares Series A Preferred stock dividend and amends charter
On May 20, 2024, amended Certificate of Incorporation to allow share dividends between classes/series.
-
Regen Biopharma dismisses auditor BF Borgers due to SEC cease-and-desist order
BF Borgers CPA PC dismissed as independent auditor effective May 10, 2024, following SEC order of May 3, 2024.
-
Regen Biopharma issues 20,068 Series A Preferred shares for consulting; amends sublease
Issued 20,068 Series A Preferred shares to Value Quest Inc. for one-year social media consulting services.
Earnings & guidance
Materiality & sentiment trend
Max materiality 0.85 · Median 0.60 · Most common event other_material